Skip to main content

Table 3 Associations between FACIT-F and (a) MOS-SS, (b) SF-36, and (c) disease activity, and between (d) SF-36 and disease activity at month 6 across treatment groupsa

From: The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials

  1. Data were pooled from Phase 3 ORAL Scan, ORAL Standard, and ORAL Sync study datasets, and are presented for the full analysis set
  2. aAll treatments were administered in combination with background conventional synthetic disease-modifying antirheumatic drugs
  3. bBased on six items of the MOS-SS: How often over the past 4 weeks did you … have trouble falling asleep; awaken during sleep; awaken short of breath/headache; get enough sleep to feel rested upon waking; get amount of sleep needed; have trouble staying awake?
  4. All correlations differed from zero at p < 0.001, except where noted as not significant
  5. BID, twice daily; CDAI, Clinical Disease Activity Index; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MCS, Mental Component Summary; MOS-SS, Medical Outcomes Study Sleep scale; NS, not significant; PCS, Physical Component Summary; Q2W, once every 2 weeks; SF-36, Short Form-36 Health Survey